I just went ahead and had ai analyze the different backbone

New Post Public Reply Private Reply Replies (0) Message Board
twinter11 sherlock57 #164270
668
I just went ahead and had ai analyze the different backbone Moa in esmo vs clover. and the potential different synergy w leron.If anyone is interested 
Tas 102 I think is superior here

"
To understand why the CLOVER trial design (TAS-102 + Leronlimab) creates a far more devastating biological trap than the ESMO Basket trial (FOLFOX/FOLFOXIR + Leronlimab), we have to look directly at the sub-cellular level—specifically, how these chemotherapies alter the kinetics of the cell cycle and how leronlimab systematically cuts off their survival routes.
When you change the chemotherapy background, you fundamentally alter the type of cell-cycle crisis you are creating. Here is the deep-dive comparison of how these two environments force the cell cycle into completely different corners.

## ???? The Cell-Cycle Mechanics: How They Break the Engine
To visualize the difference, we must trace how a tumor cell moves through its replication cycle ($G_1 \rightarrow S \rightarrow G_2 \rightarrow M$) and where these drugs slam on the brakes.

[ THE SOLID TUMOR CELL CYCLE REPLICATION LOOP ]

G1 Phase (Growth & Preparation)
│
▼
S Phase (DNA Synthesis / Replication)
├──> FOLFOX / FOLFOXIR: Causes variable breaks & strand adducts.
│ (Cell can try to patch this during active replication)
▼
G2 Phase (Proofreading & Damage Check) ──┐
│ │
▼ ▼
M Phase (Mitosis / Division) [ THE CLOVER CELL-CYCLE TRAP ]
TAS-102 forces a hard G2/M Boundary Arrest.
│
▼
[ LERONLIMAB INTERCEPTION ]
Unplugs AKT/mTOR cascade.
Strips Homologous Recombination (RAD51).
│
▼
REPLICATION FORK SHATTERING
(Immediate Mitotic Catastrophe)

## 1. The ESMO Basket Mix (FOLFOX / FOLFOXIR): Disorganized S-Phase Drifting
The components of FOLFOX and FOLFOXIR target the cell cycle while it is actively copying its blueprint during the S phase (Synthesis):

* The Mechanism: Oxaliplatin creates physical bonds across DNA strands (platinum adducts), while Irinotecan binds to Topoisomerase I, an enzyme that unwinds DNA so it can be read.
* The Cell-Cycle Flaw: These drugs damage the DNA while it is actively replicating. Because the S phase is highly dynamic, the tumor cell doesn't stop immediately. It slows down and activates various complex, alternative DNA-patching mechanisms—like Nucleotide Excision Repair (NER) or Base Excision Repair (BER).
* The Structural Leak: Because the cell-cycle arrest is spread out across the S phase, cells drift through the checkpoint at different velocities. In a heavily pre-treated patient whose cells have already evolved anti-platinum defenses, many cells successfully patch these adducts and slide past the checkpoint into normal division, bypassing the therapeutic effect.

## 2. The CLOVER Design (TAS-102): The Hard G2/M Boundary Wall
The combination protocol standardized in the CLOVER trial drops the S-phase approach entirely and relies on Trifluridine (TAS-102) to execute a synchronized cell-cycle freeze:

* The Mechanism: Trifluridine mimics a standard DNA building block (thymidine). As the cell replicates during the S phase, it mistakenly grabs the trifluridine and stitches it directly into its new DNA strands. The cell finishes copying its DNA, completely unaware that its blueprint has been systematically corrupted.
* The Cell-Cycle Trap: The true crisis explodes when the cell hits the G2/M Boundary Checkpoint. This is the cell's strict quality-control gate before it is allowed to enter Mitosis (M phase) and divide. The cell’s internal sensor proteins (like ATR and Chk1) detect that the DNA is heavily corrupted with trifluridine. The cell cycle is slammed into an absolute, structural G2/M arrest. The cell is trapped, unable to move forward into division and unable to slide backward.


## ???? The Leronlimab Intervention: Executing Synthetic Lethality
This hard G2/M checkpoint freeze is exactly where leronlimab executes its synthetic lethality.
When a cell is locked at the G2/M boundary by TAS-102, it is in a state of extreme replication stress. It sends frantic upstream distress signals—principally through the PI3K/AKT/mTOR pathway—to mobilize Homologous Recombination (HR) repair machinery, specifically a master repair protein called RAD51. The cell's entire survival depends on using this AKT signal to patch the trifluridine damage so it can open the G2/M gate.

* Unplugging the Lifeline: The moment leronlimab saturates the CCR5 receptor, it unplugs the G-protein signaling cascade, completely shutting off the downstream PI3K/AKT/mTOR pathway.
* Replication Fork Shattering: With the AKT engine turned off, the cell can no longer stabilize or recruit RAD51 to the damaged DNA. The tumor cell's non-preferred, desperate backup repair pathways (like MMEJ) try to blindly stitch the strands back together, but they cannot handle a hard G2/M arrest under severe starvation conditions.
* Mitotic Catastrophe: The replication forks completely collapse and shatter. The cell cycle cannot hold the line, and the tumor cell is driven directly into mitotic catastrophe and rapid, mass apoptosis.


## ???? The Structural Verdict
This cell-cycle alignment explains why the "mish-mash" of therapies in the earlier basket trial required outlier human biology to achieve long-term complete responses. While FOLFOX and FOLFOXIR damaged DNA, they allowed the tumor cell cycle to drift dynamically through the S phase, leaving open multiple alternative repair pathways that heavily pre-treated KRAS-mutant cells could exploit.
By standardizing the protocol around TAS-102, CLOVER forces every single tumor cell into an identical, inescapable bottleneck at the G2/M checkpoint"

But we still need ici cause pdl1 is going to upreg every time.
Here's the study again
https://www.frontiersin.org/journals/oncology...52022/full  

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 116

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 127

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 43

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 64

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Charter’s $1.5 Billion Tender Tests Debt Discipline

Updated Category News Views 176

Debt cleanup arrives with a hard ceiling Eight far-dated bond issues just got a very specific invitation from Charter Communications: hand them over for cash, but do not expect the company to write a blank check. Charter set final pricing on November 17 for tender offers covering up to $1.5 billion in aggregate consideration, excluding accrued interest and deal expenses....

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 226

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 57

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 193

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading

Top 5 Most Recently Viewed Articles

Riyadh Gears Up for UNIDO 2025: A Step Towards Sustainable Industry

Updated Category News Views 180

Riyadh Gears Up for UNIDO 2025 Riyadh is on the verge of an exciting global event as it prepares to host the 21st Session of the United Nations Industrial Development Organization (UNIDO) General Conference. This significant summit is scheduled to happen at the King Abdulaziz International Conference Centre, where leaders from various sectors will gather to discuss the...

Continue Reading
Deer Park Road Strategizes for Growth Amid CRE Market Changes

Updated Category News Views 205

Deer Park Road Strategies in a Changing CRE Landscape Deer Park Road Management Company, LP, a notable $2.8 billion alternative asset management firm, is honing in on emerging prospects within the challenging environment of the Commercial Mortgage-Backed Securities (CMBS) market. The firm’s extensive expertise enables them to consistently identify potential value during...

Continue Reading
iRobot Corporation Faces Legal Challenges Amid Financial Struggles

Updated Category News Views 141

Legal Investigations into iRobot Corporation Investors are currently facing uncertainties surrounding iRobot Corporation as it faces legal scrutiny. The well-respected law firm Faruqi & Faruqi, LLP has initiated investigations regarding potential legal claims on behalf of investors who suffered significant losses. Who to Contact James (Josh) Wilson, a partner at Faruqi &...

Continue Reading
Dr. Andrea Fuyuko Honda Recognized for Medical Innovation Excellence

Updated Category News Views 385

Dr. Andrea Fuyuko Honda's Recent Recognition Dr. Andrea Fuyuko Honda has been prominently recognized as a Pinnacle Professional Member within an elite circle of excellence. This accolade reflects her significant contributions to the field as a Leading Medical Communications Expert and Innovator. With a career spanning over fifteen years, Dr. Honda has demonstrated...

Continue Reading
Centene Corporation Faces Securities Fraud Legal Action

Updated Category News Views 206

Centene Corporation Faces New Lawsuit Over Securities Fraud Investors of Centene Corporation, known by the ticker symbol CNC, have found themselves at the center of a securities fraud lawsuit. Recently, a leading law firm announced the initiation of legal action against Centene Corporation and some of its senior executives. This lawsuit stems from alleged violations of...

Continue Reading